Good afternoon. Welcome to SAGE Therapeutics first quarter 2025 financial results conference call. (Operator Instructions). This call is being webcast live on the investors and media section of ...

Sage Therapeutics, Inc. SAGE reported a loss of $1.01 per share for the first quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 99 cents. The company had reported a loss of $1. ...

Good afternoon. Welcome to Sage Therapeutics First Quarter 2025 Financial Results Conference Call. [Operator Instructions] This call is being webcast live on the Investors and Media section of ...

Sage Therapeutics demonstrated strong commercial performance for ZURZUVAE in Q1 2025, driven by growing demand and expanded prescriber engagement. Strategic investments in promotional efforts and ...

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to loss of $1.80 per share a year ago.

Sage Therapeutics reported a net loss of $62.2 million for Q1 2025, with an earnings per share (EPS) of -1.01, slightly missing the forecast of -0.99. Revenue reached $14.06 million, falling short ...

Cash runway expected to support operations to mid-2027 Strategic alternatives review process remains ongoing Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and ...

Good afternoon. Welcome to SAGE Therapeutics first quarter 2025 financial results conference call. (Operator Instructions). This call is being webcast live on the investors and media section of Sage's ...

Sage Therapeutics, Inc. SAGE reported a loss of $1.01 per share for the first quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 99 cents. The company had reported a loss of $1.80 ...